Shanghai Saierxin Biomedical Technology

Novabiotx (Shanghai Saierxin Biomedical Technology) is a clinical-stage biotechnology company focused on developing innovative Regulatory T cell (Treg) therapies for neurodegenerative, autoimmune, and metabolic diseases. Founded in 2022 and headquartered in Shanghai, the company leverages its multimodal Treg platform to address conditions with high unmet medical needs, such as Amyotrophic Lateral Sclerosis (ALS) and Multiple System Atrophy (MSA). Its lead candidate, NP001, is an autologous polyclonal Treg cell injection that has received IND approval in both China and the United States and is currently in Phase 1/2 clinical trials. Novabiotx is also exploring exosome-based therapies and other cell-based modalities to expand its pipeline in the field of regenerative medicine and immune modulation.